These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 22799115)

  • 41. Visceral leishmaniasis infection in a refractory multiple myeloma patient treated with bortezomib.
    Piro E; Kropp M; Cantaffa R; Lamberti AG; Carillio G; Molica S
    Ann Hematol; 2012 Nov; 91(11):1827-8. PubMed ID: 22584850
    [No Abstract]   [Full Text] [Related]  

  • 42. Anti-angiogenic effect of bortezomib in patients with multiple myeloma.
    Politou M; Naresh K; Terpos E; Crawley D; Lampert I; Apperley JF; Rahemtulla A
    Acta Haematol; 2005; 114(3):170-3. PubMed ID: 16227683
    [No Abstract]   [Full Text] [Related]  

  • 43. Interstitial pneumonitis caused by Pneumocystis jirovecii pneumonia (PCP) during bortezomib treatment.
    Wondergem MJ; Grünberg K; Wittgen BP; Sonneveld P; Zweegman S
    Histopathology; 2009 Apr; 54(5):631-3. PubMed ID: 19302537
    [No Abstract]   [Full Text] [Related]  

  • 44. Bortezomib-induced tumor lysis syndrome in multiple myeloma.
    Sezer O; Vesole DH; Singhal S; Richardson P; Stadtmauer E; Jakob C; Boral AL; Esseltine DL; Mehta J
    Clin Lymphoma Myeloma; 2006 Nov; 7(3):233-5. PubMed ID: 17229340
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficacy of bortezomib therapy for extramedullary relapse of myeloma after autologous and non-myeloablative allogeneic transplantation.
    Patriarca F; Prosdocimo S; Tomadini V; Vasciaveo A; Bruno B; Fanin R
    Haematologica; 2005 Feb; 90(2):278-9. PubMed ID: 15710593
    [TBL] [Abstract][Full Text] [Related]  

  • 46. No evidence of mutations of the PSMB5 (beta-5 subunit of proteasome) in a case of myeloma with clinical resistance to Bortezomib.
    Politou M; Karadimitris A; Terpos E; Kotsianidis I; Apperley JF; Rahemtulla A
    Leuk Res; 2006 Feb; 30(2):240-1. PubMed ID: 16081156
    [No Abstract]   [Full Text] [Related]  

  • 47. Clinical management of myeloma--state of the art.
    Harousseau JL
    Cancer Treat Rev; 2010 May; 36 Suppl 2():S1-2. PubMed ID: 20472182
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Follicular keratosis and multiple myeloma].
    García-Romero D; Sanz-Robles H; Arrue I; Sánchez-Largo ME; Rodríguez-Peralto JL; Vanaclocha F
    Actas Dermosifiliogr; 2006 Nov; 97(9):599-602. PubMed ID: 17173767
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Bortezomib and bilateral herpes zoster.
    di Meo N; Bergamo S; Dondas A; Trevisan G
    Acta Dermatovenerol Alp Pannonica Adriat; 2012; 21(1):21-2. PubMed ID: 22584902
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Captivating bortezomib: an active but still mysterious drug.
    Di Raimondo F; Conticello C
    Leuk Res; 2010 Apr; 34(4):411-2. PubMed ID: 19819547
    [No Abstract]   [Full Text] [Related]  

  • 51. Resolution of bilateral cystoid macular edema and subfoveal serous retinal detachments after treatment with bortezomib in a patient with "smoldering" multiple myeloma.
    Grannis CH; Dewan VN; Wang RC
    Retin Cases Brief Rep; 2014; 8(4):348-51. PubMed ID: 25372546
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Bortezomib in multiple myeloma.
    Cecchi M; Caccese E; Messori A
    N Engl J Med; 2005 Sep; 353(12):1297-8; author reply 1297-8. PubMed ID: 16177258
    [No Abstract]   [Full Text] [Related]  

  • 53. Bone marrow angiogenesis and angiogenic factors in multiple myeloma treated with novel agents.
    Cibeira MT; Rozman M; Segarra M; Lozano E; Rosiñol L; Cid MC; Filella X; Bladé J
    Cytokine; 2008 Mar; 41(3):244-53. PubMed ID: 18178097
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A new combination for advanced multiple myeloma.
    Palumbo A; Gay F
    Lancet Oncol; 2011 Mar; 12(3):207-8. PubMed ID: 21345727
    [No Abstract]   [Full Text] [Related]  

  • 55. Newer treatment options for patients in first relapse. From the Multiple Myeloma Research Foundation.
    Richardson P
    Oncology (Williston Park); 2006 May; 20(6):633-8. PubMed ID: 16773847
    [No Abstract]   [Full Text] [Related]  

  • 56. Drug pricing: No cure, no cost.
    Jack A
    BMJ; 2007 Jul; 335(7611):122-3. PubMed ID: 17641343
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A modified regimen of pegylated liposomal doxorubicin, bortezomib, and dexamethasone is effective and well tolerated in the treatment of relapsed or refractory multiple myeloma.
    Waterman GN; Yellin O; Swift RA; Mapes R; Eades B; Ackerman E; Berenson JR
    Ann Hematol; 2011 Feb; 90(2):193-200. PubMed ID: 20809423
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature.
    Badros A; Goloubeva O; Dalal JS; Can I; Thompson J; Rapoport AP; Heyman M; Akpek G; Fenton RG
    Cancer; 2007 Sep; 110(5):1042-9. PubMed ID: 17654660
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Multiple myeloma.
    Raab MS; Podar K; Breitkreutz I; Richardson PG; Anderson KC
    Lancet; 2009 Jul; 374(9686):324-39. PubMed ID: 19541364
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Bortezomib in multiple myeloma.
    Mateos MV; San Miguel JF
    Best Pract Res Clin Haematol; 2007 Dec; 20(4):701-15. PubMed ID: 18070714
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.